{"id":612519,"date":"2022-08-18T18:56:01","date_gmt":"2022-08-18T18:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=612519"},"modified":"2022-08-18T18:56:01","modified_gmt":"2022-08-18T18:56:01","slug":"anticd19-antibody-pipeline-report-companies-sanofi-incyte-corporation-amgen-viela-bio-tg-therapeutics-merck-kgaa-generium-pharmaceutical-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/anticd19-antibody-pipeline-report-companies-sanofi-incyte-corporation-amgen-viela-bio-tg-therapeutics-merck-kgaa-generium-pharmaceutical-and-others_612519.html","title":{"rendered":"Anti-CD19 Antibody Pipeline Report | Companies- Sanofi, Incyte Corporation, Amgen, Viela Bio, TG Therapeutics, Merck kGaA, Generium Pharmaceutical, and others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1660795305.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Anti-CD19 Antibody Pipeline Report | Companies- Sanofi, Incyte Corporation, Amgen, Viela Bio, TG Therapeutics, Merck kGaA, Generium Pharmaceutical, and others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1660795305.jpeg\" alt=\"Anti-CD19 Antibody Pipeline Report | Companies- Sanofi, Incyte Corporation, Amgen, Viela Bio, TG Therapeutics, Merck kGaA, Generium Pharmaceutical, and others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Anti-CD19 Antibody Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong><em>Approximately 15+ key companies are developing&nbsp;Anti-CD19 Antibody. The companies with their Anti-CD19 Antibody-drug candidates in the most advanced stage include Viela Bio,&nbsp;ADC Therapeutics, Amgen,&nbsp;Morphosys and Xencor.<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<strong>Anti-CD19 Antibody Pipeline Insight<\/strong>&rdquo; report provides comprehensive insights about&nbsp;<strong>15+&nbsp;<\/strong>companies and&nbsp;<strong>15+&nbsp;<\/strong>pipeline drugs in the Anti-CD19 Antibody pipeline landscapes. It comprises Anti-CD19 Antibody pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Anti-CD19 Antibody therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Anti-CD19 Antibody pipeline products.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways of the&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/anti-cd19-antibody-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>Anti-CD19 Antibody Pipeline Report<\/strong><\/a><strong>&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Notable companies such as<strong>&nbsp;TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio,<\/strong>&nbsp;and others are developing potential drug candidates to boost the Anti-CD19 Antibody treatment scenario.&nbsp;<\/li>\n<li>In&nbsp;<strong>April 2021<\/strong>, Incyte and MorphoSys announced the first patient had been dosed in the placebo-controlled Phase 3&nbsp;<em>inMIND&nbsp;<\/em>study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).<\/li>\n<li>In&nbsp;<strong>March 2021<\/strong>, Amgen reported positive data from the Phase III study of BLINCYTO (blinatumomab) in paediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukaemia (B-ALL).<\/li>\n<li>In&nbsp;<strong>February 2021<\/strong>, Viela Bio announced additional positive results with UPLIZNA (inebilizumab-cdon) in patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum.<\/li>\n<li>In&nbsp;<strong>November 2020<\/strong>, Xencor, MorphoSys and Incyte announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), first-line DLBCL, and relapsed or refractory follicular lymphoma (FL).<\/li>\n<li>In&nbsp;<strong>June 2020<\/strong>, inebilizumab received its first global approval in the USA for the Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment in adult patients who are seropositive for immunoglobulin G autoantibodies against aquaporin-4 (AQP4-IgG). The drug is also undergoing clinical evaluation for kidney transplant desensitisation, myasthenia gravis, and IgG4-related disease.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/400fecfba504d2f8fead527b45fa2c8d.jpg\" alt=\"\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get an overview of pipeline landscape @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anti-cd19-antibody-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Anti-CD19 Antibody Clinical Trials Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Anti-CD19 Antibody, a cluster of differentiation 19 (CD19), is a cell surface molecule expressed on B- lineage cells and follicular dendritic cells. CD19 comprises two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. It functions as a positive regulator of B-cell receptor signalling in conjunction with CD21 and CD81.&nbsp; CD19 is expressed throughout B-cell development and plays a critical role in maintaining the balance between humoral, antigen-induced immune response and tolerance induction.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Anti-CD19 Antibody Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Inebilizumab: Viela Bio<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Inebilizumab&nbsp;<\/strong>is a humanised monoclonal antibody designed to target and deplete CD19-expressing B cells through antibody-dependent cell-mediated cytotoxicity.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Research and Development<\/strong> <strong>Myasthenia Gravis<\/strong> <strong>Phase III<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>NCT04524273:&nbsp;<\/strong>In August 2020<strong>, Viela Bio i<\/strong>nitiated a randomised, double-blind, multicenter, placebo-controlled Phase 3 study with an open-label period to assess the efficacy and safety of Inebilizumab in adults with Myasthenia Gravis. This study is a phase 3, randomised, double-blind, placebo-controlled study conducted at approximately 100 study sites. About 252 subjects (172 AChR-Ab+ and 80 MuSK-Ab+) will be enrolled. The study is estimated to get completed by December 2024 with 252 registered participants.<\/p>\n<p style=\"text-align: justify;\"><strong>IgG4-Related Disease&nbsp;<\/strong> <strong>Phase III<\/strong> <strong>NCT04540497:<\/strong>&nbsp;In October 2020,&nbsp;<strong>Viela Bio<\/strong>&nbsp;initiated a Phase 3, randomised, double-blind, multicenter, and placebo-controlled study of Inebilizumab efficacy and safety in IgG4-Related Disease. This study focuses on defining the effectiveness and safety of Inebilizumab for the prevention of flare of IgG4-related disease (IgG4-RD). The study is estimated to get completed by June 2024 with 160 enrolled participants.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>For further information, refer to the detailed report @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anti-cd19-antibody-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>Anti-CD19 Antibody Pipeline Therapeutics<\/strong><\/a><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of&nbsp;Anti-CD19 Antibody Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage:&nbsp;<\/strong>Global&nbsp;<\/li>\n<li><strong>Major Players: 15+&nbsp; Key Players<\/strong><\/li>\n<li><strong>Prominent Players:&nbsp;<\/strong>TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and many others.&nbsp;&nbsp;&nbsp;<\/li>\n<li><strong>Key Drugs Profiles: 15+ Products<\/strong><\/li>\n<li><strong>Phases:&nbsp;&nbsp;<\/strong><\/li>\n<li><strong>Mechanism of Action:<\/strong><\/li>\n<li><strong>Molecule Types:&nbsp;&nbsp;&nbsp;<\/strong><\/li>\n<li><strong>Route of Administration:<\/strong><\/li>\n<li><strong>Product Types:<\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Anti-CD19 Antibody Therapies Late-stage (Phase III)&nbsp;&nbsp;<\/li>\n<li>Anti-CD19 Antibody Therapies Mid-stage (Phase II)<\/li>\n<li>Anti-CD19 Antibody Therapies Early-stage (Phase I)&nbsp;<\/li>\n<li>Anti-CD19 Antibody Pre-clinical stage and Discovery candidates&nbsp;&nbsp;&nbsp;<\/li>\n<li>Discontinued and Inactive candidates&nbsp;<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>CD-19 Antagonist<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Antibody<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Intravenous&nbsp;&nbsp;<\/li>\n<li>Parenteral<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Monotherapy<\/li>\n<li>Combination<\/li>\n<li>Mono\/Combination&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Questions regarding&nbsp;Current Anti-CD19 Antibody Treatment Landscape&nbsp;and Emerging Therapies Answered in the Pipeline Report &nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for Anti-CD19 Antibody treatment?<\/li>\n<li>How many companies are developing therapies for the treatment of Anti-CD19 Antibody?&nbsp;<\/li>\n<li>How many are Anti-CD19 Antibody emerging therapies in the early-stage, mid-stage, and late development stages to treat Anti-CD19 Antibody?<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Anti-CD19 Antibody market?&nbsp;<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of Anti-CD19 Antibody?&nbsp;&nbsp;<\/li>\n<li>What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Anti-CD19 Antibody therapies?&nbsp;<\/li>\n<li>What are the critical designations that have been granted for the emerging therapies for Anti-CD19 Antibody?&nbsp;<\/li>\n<li>How many patents are granted and pending for the emerging therapies to treat Anti-CD19 Antibody?&nbsp; &nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table border=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p><strong>1<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody&nbsp;Report&nbsp;Introduction<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>2<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody Executive Summary<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>3<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody&nbsp;Overview<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>4<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody &ndash; DelveInsight&rsquo;s Analytical Perspective In-depth Commercial Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>5<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody Pipeline Therapeutics<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>6<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody&nbsp;Late Stage Products (Phase III)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.1<\/p>\n<\/td>\n<td width=\"493\">\n<p>Inebilizumab : Viela Bio<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>7<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody<\/strong>&nbsp;<strong>Mid Stage Products (Phase II)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.1<\/p>\n<\/td>\n<td width=\"493\">\n<p>&nbsp;Coltuximab ravtansine : Sanofi<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>8<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody Early Stage Products (Phase I\/II)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8.1<\/p>\n<\/td>\n<td width=\"493\">\n<p>GNR-084: Generium Pharmaceutical<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>9<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody Early Stage Products (Phase I)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9.1<\/p>\n<\/td>\n<td width=\"493\">\n<p>DI-B4: Merck KGaA<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>10<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody Therapeutic Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>11<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody Inactive Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>12<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Company-University Collaborations (Licensing\/Partnering) Analysis<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>13<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody Key Companies<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>14<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody Key Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>15<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody Unmet Needs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>16&nbsp;<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody Market Drivers and Barriers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>17<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody&nbsp;Future Perspectives and Conclusion<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>18<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Anti-CD19 Antibody&nbsp;Analyst Views<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>19<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>Appendix<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>20<\/strong><\/p>\n<\/td>\n<td width=\"493\">\n<p><strong>About DelveInsight<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Get a customised pipeline report @<\/strong>&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anti-cd19-antibody-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Anti-CD19 Antibody Drugs Pipeline Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Other Trending Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hip-reconstruction-devices-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Hip Replacement Devices Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">Hip Reconstruction\/Replacement Devices Market Insights, Competitive Landscape and Market Forecast-2027 report delivers an in-depth understanding of Hip Reconstruction\/Replacement Devices and the historical and forecasted Hip Reconstruction\/Replacement Devices market trends in the 7MM.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides&nbsp;Portfolio Management Services&nbsp;to understand the competencies, leverage strengths to prioritise strategic goals and understand the market&rsquo;s current needs.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=anticd19-antibody-pipeline-report-companies-sanofi-incyte-corporation-amgen-viela-bio-tg-therapeutics-merck-kgaa-generium-pharmaceutical-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/anti-cd19-antibody-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/anti-cd19-antibody-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/anti-cd19-antibody-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=anticd19-antibody-pipeline-report-companies-sanofi-incyte-corporation-amgen-viela-bio-tg-therapeutics-merck-kgaa-generium-pharmaceutical-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anti-CD19 Antibody Pipeline Approximately 15+ key companies are developing&nbsp;Anti-CD19 Antibody. The companies with their Anti-CD19 Antibody-drug candidates in the most advanced stage include Viela Bio,&nbsp;ADC Therapeutics, Amgen,&nbsp;Morphosys and Xencor. DelveInsight&rsquo;s &ldquo;Anti-CD19 Antibody Pipeline Insight&rdquo; report provides comprehensive insights about&nbsp;15+&nbsp;companies and&nbsp;15+&nbsp;pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/anticd19-antibody-pipeline-report-companies-sanofi-incyte-corporation-amgen-viela-bio-tg-therapeutics-merck-kgaa-generium-pharmaceutical-and-others_612519.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,413,404],"tags":[],"class_list":["post-612519","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/612519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=612519"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/612519\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=612519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=612519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=612519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}